Sökning: WFRF:(Guo Yichen) >
EGLN2 DNA methylati...
EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC
-
- Zhang, Ruyang (författare)
- Harvard University,Nanjing Medical University
-
- Lai, Linjing (författare)
- Nanjing Medical University
-
- He, Jieyu (författare)
- Nanjing Medical University
-
visa fler...
-
- Chen, Chao (författare)
- Nanjing Medical University
-
- You, Dongfang (författare)
- Nanjing Medical University
-
- Duan, Weiwei (författare)
- Nanjing Medical University
-
- Dong, Xuesi (författare)
- Nanjing Medical University,Southeast University
-
- Zhu, Ying (författare)
- Nanjing Medical University
-
- Lin, Lijuan (författare)
- Nanjing Medical University
-
- Shen, Sipeng (författare)
- Harvard University,Nanjing Medical University
-
- Guo, Yichen (författare)
- Harvard University
-
- Su, Li (författare)
- Nanjing Medical University,Harvard University
-
- Shafer, Andrea (författare)
- Massachusetts General Hospital,Harvard University
-
- Moran, Sebastian (författare)
- Bellvitge Biomedical Research Institute,University of Barcelona,Catalan Institution for Research and Advanced Studies
-
- Fleischer, Thomas (författare)
- Oslo university hospital
-
- Bjaanæs, Maria Moksnes (författare)
- Oslo university hospital
-
- Karlsson, Anna (författare)
- Lund University,Lunds universitet,Forskningsgrupp Lungcancer,Forskargrupper vid Lunds universitet,Research Group Lung Cancer,Lund University Research Groups
-
- Planck, Maria (författare)
- Lund University,Lunds universitet,Forskningsgrupp Lungcancer,Forskargrupper vid Lunds universitet,Research Group Lung Cancer,Lund University Research Groups
-
- Staaf, Johan (författare)
- Lund University,Lunds universitet,Forskningsgrupp Lungcancer,Forskargrupper vid Lunds universitet,Research Group Lung Cancer,Lund University Research Groups
-
- Helland, Åslaug (författare)
- Oslo university hospital,University of Oslo
-
- Esteller, Manel (författare)
- Bellvitge Biomedical Research Institute,Catalan Institution for Research and Advanced Studies,University of Barcelona
-
- Wei, Yongyue (författare)
- Nanjing Medical University,Harvard University
-
- Chen, Feng (författare)
- Nanjing Medical University
-
- Christiani, David C. (författare)
- Massachusetts General Hospital,Nanjing Medical University,Harvard University
-
visa färre...
-
(creator_code:org_t)
- 2019-01-31
- 2019
- Engelska.
-
Ingår i: Epigenetics. - : Informa UK Limited. - 1559-2294 .- 1559-2308. ; 14:2, s. 118-129
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://www.tandfonl...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Hypoxia occurs frequently in human cancers and promotes stabilization and activation of hypoxia inducible factor (HIF). HIF-1α is specific for the hypoxia response, and its degradation mediated by three enzymes EGLN1, EGLN2 and EGLN3. Although EGLNs expression has been found to be related to prognosis of many cancers, few studies examined DNA methylation in EGLNs and its relationship to prognosis of early-stage non-small cell lung cancer (NSCLC). We analyzed EGLNs DNA methylation data from tumor tissue samples of 1,230 early-stage NSCLC patients, as well as gene expression data from The Cancer Genome Atlas. The sliding windows sequential forward feature selection method and weighted random forest were used to screen out the candidate CpG probes in lung adenocarcinomas (LUAD) and lung squamous cell carcinomas patients, respectively, in both discovery and validation phases. Then Cox regression was performed to evaluate the association between DNA methylation and overall survival. Among the 34 CpG probes in EGLNs, DNA methylation at cg25923056EGLN2 was identified to be significantly associated with LUAD survival (HR = 1.02, 95% CI: 1.01–1.03, P = 9.90 × 10–5), and correlated with EGLN2 expression (r =–0.36, P = 1.52 × 10–11). Meanwhile, EGLN2 expression was negatively correlated with HIF1A expression in tumor tissues (r =–0.30, P = 4.78 × 10–8) and significantly (P = 0.037) interacted with HIF1A expression on overall survival. Therefore, DNA methylation of EGLN2- HIF1A is a potential marker for LUAD prognosis and these genes are potential treatment targets for further development of HIF-1α inhibitors in lung cancer therapy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Medicinsk genetik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Medical Genetics (hsv//eng)
Nyckelord
- DNA methylation
- EGLN2
- HIF1A
- lung cancer
- prognosis
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Zhang, Ruyang
-
Lai, Linjing
-
He, Jieyu
-
Chen, Chao
-
You, Dongfang
-
Duan, Weiwei
-
visa fler...
-
Dong, Xuesi
-
Zhu, Ying
-
Lin, Lijuan
-
Shen, Sipeng
-
Guo, Yichen
-
Su, Li
-
Shafer, Andrea
-
Moran, Sebastian
-
Fleischer, Thoma ...
-
Bjaanæs, Maria M ...
-
Karlsson, Anna
-
Planck, Maria
-
Staaf, Johan
-
Helland, Åslaug
-
Esteller, Manel
-
Wei, Yongyue
-
Chen, Feng
-
Christiani, Davi ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Medicinsk geneti ...
- Artiklar i publikationen
-
Epigenetics
- Av lärosätet
-
Lunds universitet